Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

405
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
405
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

634
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
634
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

606
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
606
Dementia01:30

Dementia

410
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
410
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

223
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
223

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating the Complexity and Heterogeneity of Thrombectomy Decision-Making for Medium-Vessel Occlusion Stroke: Where Do We Go From Here?

Stroke (Hoboken, N.J.)·2026
Same author

Physician Approaches to Determining Goals of Stroke Care for Patients Living With Disability or Dementia: Results from the SEED Mixed-Methods Study.

Stroke·2026
Same author

Association of Successful Recanalization and Functional Outcomes in Minor Ischemic Stroke With Proven Occlusion: A Secondary Analysis of TEMPO-2 Trial.

Stroke·2026
Same author

Phase 2 Futility Trials in Alzheimer Disease and Mild Cognitive Impairment: A Cohort Analysis of the ADNI Data Set.

Neurology·2026
Same author

Predictors and Consequences of Serious Adverse Events in Patients Treated With Thrombolysis: A Prespecified Secondary Analysis of the AcT Trial.

Journal of the American Heart Association·2026
Same author

Reperfusion Therapy in ESCAPE-MeVO Trial Participants: Imaging Characteristics and Clinical Outcomes.

Radiology·2026

Related Experiment Video

Updated: Dec 7, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.8K

Practice Current: How do you manage mild cognitive impairment?

Aravind Ganesh1, Padmaja Genesh1, Malik M Adil1

  • 1Department of Clinical Neurosciences (AG), University of Calgary; Learning and Support Services (PG), Alzheimer Society of Calgary, Canada; Johns Hopkins University School of Medicine (MMA), Bethesda, MD; Advanced Health Analytics (AHA Health Ltd) (MV), Calgary, and Katthy Taylor Chair in Vascular Dementia (EES), Department of Clinical Neurosciences, University of Calgary, Canada.

Neurology. Clinical Practice
|September 28, 2020
PubMed
Summary
This summary is machine-generated.

Expert opinions and survey results address uncertainties in diagnosing and treating mild cognitive impairment (MCI), guiding clinicians on advanced investigations and pharmacologic options for patients with cognitive decline.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.5K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.4K

Related Experiment Videos

Last Updated: Dec 7, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.8K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.5K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.4K

Area of Science:

  • Neurology
  • Geriatrics
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) presents cognitive deficits with minimal impact on daily living, yet poses a significant risk for dementia progression.
  • Current guidelines recommend a limited workup for MCI, focusing on reversible causes.
  • Recent advancements include sophisticated imaging, biomarkers, and genetic tests, but their clinical utility remains unclear.

Purpose of the Study:

  • To gather global expert opinions on the investigation and management of patients with mild cognitive impairment (MCI).
  • To address uncertainties surrounding the use of advanced diagnostic tools and pharmacologic treatments for MCI.
  • To present preliminary results from an online survey of neurologists regarding MCI workup and treatment.

Main Methods:

  • Solicited expert opinions from neurologists worldwide on optimal MCI investigation and treatment strategies.
  • Conducted an online survey among neurologists to gather insights on current practices and uncertainties in MCI management.
  • Analyzed expert opinions and preliminary survey data to identify consensus and areas of equipoise.

Main Results:

  • Identified significant uncertainties among experts and clinicians regarding the role of advanced investigations in routine MCI practice.
  • Highlighted the lack of consensus on the use of cholinesterase inhibitors and other pharmacologic agents for MCI.
  • Preliminary survey data indicate a need for clearer guidelines on both diagnostic workup and therapeutic interventions for MCI.

Conclusions:

  • There is a pressing need for high-quality data to guide the investigation and treatment of mild cognitive impairment (MCI).
  • Expert consensus and clinician surveys reveal significant uncertainties in managing MCI, particularly concerning advanced diagnostics and pharmacologic options.
  • Further research is crucial to establish evidence-based guidelines for the effective management of patients with MCI.